About Us
- About Us
- Vision
- Mission
- Mandate
- Objectives
- ECaPPH Policies
- Governance Structure
- Our committees
ECaPPH is a unique bio-innovation and bio-fabrication ecosystem co-led by three Quebec universities (Université de Montréal - McGill University - Université Laval), with the mission of providing Canada with a resilient and agile response to future pandemics and health threats. To achieve this, ECaPPH focuses on building research and training capacity, and promoting and facilitating collaboration between institutional, not-for-profit, industry, private and/or public partners.
ECaPPH's mission is to increase the agility, connectivity and growth of the biomanufacturing and life sciences sector, so that Canada is ready to face future pandemics and health crises. ECaPPH will achieve this by bringing together the expertise and resources of industry, not-for-profit organizations, government agencies and academic institutions to establish and update strategic priorities, identify and fill gaps, create opportunities for growth, and support multi-stakeholder projects between industry and academia.
ECaPPH will support the implementation of genomics-based diagnostics and new RNA-based therapies and vaccines. It will also develop existing platforms and technologies, promote the integration of artificial intelligence (AI) and boost the production and evaluation of vaccines, small molecules and cell-based therapies for emerging infections.
Priority pathogens causing pandemics and emerging health risks. Focus on diagnostics, vaccines and therapeutics, while addressing critical gaps that slow down biomanufacturing.
Supporting training and development to strengthen the pipeline of qualified researchers and talent
Attract and develop highly-qualified personnel, such as students, post-docs, early-career researchers and industry research, engineering and biomanufacturing technicians trained in Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP).
Accelerating the transition from promising research results to commercially-viable processes and products
Strengthen the receptor capacity of public and private developers of vaccines, therapeutics and diagnostics; support the creation of intellectual property in Canada; and increase the capacity of institutions to work in collaboration with companies including those supported by the Strategic Innovatation Fund.
ECaPPH Policies
Tri-Agency Framework: Responsible Conduct of Research
- The Framework describes the Tri-Agency policies and requirements related to applying for and managing Agency funds, performing research and disseminating results, and the processes that institutions and agencies follow in the event of an allegation of a breach of an Agency policy. Researchers who apply for or hold Agency funding must adhere to the Framework.
- All research teams/projects endorsed by the ECaPPH and all ECaPPH committee members must adhere to the Framework.
Policy Statement on Research Security and COVID-19 from the Government of Canada
- The Statement exhorts researchers in the health field (in this case, especially COVID-19) to assess proactively the national security risks their research may be open to, especially from human and cyber actors abroad.
- All research teams/projects endorsed by the ECaPPH must complete a Risk Assessment form before submitting full applications to the Stage 2 CBRF/BRIF competition.
Best Practices in Equity, Diversity and Inclusion in Research
- This guide provides a general overview of systemic barriers that exist in the research ecosystem, and helps support NFRF applicants and reviewers, and the research community, in achieving greater EDI in their research.
- All ECaPPH Stage 2 full proposals will have an EDI section. Research teams are encouraged to adopt as many best practices in this guide as possible.
Statement on Conflict of Interest and Confidentiality Policy of the Federal Research Funding Organizations
- The Statement aims to ensure the effective management of conflict of interest of any participant in a review process and to ensure, during the review process, confidentiality of personal information and confidential commercial information.
- All ECaPPH council/committee members must be aware of and apply this policy in view of the significant risk of conflict, real or perceived.
Governance Structure
Our committees
Governing Council
Co-chairs
- Martha Crago, Vice-Principal - Research and Innovation, McGill University
- Yves Joanette, Vice-rector Assistant of Research, Université de Montréal
Co-lead
- Eugénie Brouillet, Vice Rector of Research and Innovation, Université Laval
Major Partner
- Jean-Pierre Perreault, Vice-President, Research and Graduate Studies, Université de Sherbrooke
- François Bertrand, Vice-President, Research and Innovation, Polytechnique Montréal
- Eileen Denovan-Wright, Professor, Department of Pharmacology, Dalhousie University
- Lisa Wise-Milestone, Strategic Lead for Pandemic Preparedness Initiative, Moderna
- Frank Béraud, CEO, Montréal InVivo
- Rasmus Rojkjaer, CEO, Haber Biologics
- Marc Sauer, CSO, BioVectra
- Carole Jabet, Scientific Director, FRQ-S
- John Glavas, AVP Vaccines, Project Management, Merck
- Magdalena Mahlstedt, Academic Partnership Manager, CASTL
- Lakshmi Krishnan, Vice-President- Life Sciences Division, NRC
Scientific Advisory Committee
Scientific Co-Directors
- Marc Ouellette, Scientific Director, Infectious and Immune Diseases axis CIHR, Université Laval
- Joanne Langley, Division Head- Infectious Diseases, Department of Pediatrics, Department of Community Health and Epidemiology, Dalhousie University
Co-lead
- Mariana Baz, Head of the Antiviral Drug Sensitivity division - The Peter Doherty Institute for infection and Immunity, Université Laval
- Sylvie Lesage, Scientific Director, Centre de recherche- Hôpital Maisonneuve-Rosemont, Université de Montréal
- Vincent Poitout, Director Research and Innovation - CHUM, Scientific Director - CRCHUM, Professor - Medecine Department - Université de Montréal
- Bruce Mazer, Professor, Department of Pediatrics, McGill University
- Steve Robbins, Director, Lady Davis Institute- Jewish General Hospital, McGill University
Major Partner
- Benoit Chabot, Professor, Microbiology and Infectious Diseases, Université Sherbrooke
- Gregory De Crescenzo, Professor, Chemical engineering Department, Polytechnique Montréal
- Sue Twine, Acting Director General, Human Health Therapeutics, National Research Council of Canada
